New Hepatitis B Treatments: What is in Evolution?

Nov 17 2024
Convention Center: Room 31 B
12:45 PM - 1:30 PM
Ticketed Event

World Class Speakers

Robert G Gish, MD
Discussion Leader

Robert G Gish, MD

Robert G Gish Consultants LLC
Maria MB Buti, MD, FAASLD
Discussion Leader

Maria MB Buti, MD, FAASLD

Hospital Valle Hebron

Description

Speakers provide updates on new curative-intent HBV medications in development and what is new in the HBV treatment development landscape. 
 

Journey Maps

Objectives

  • Describe the new targets of HBV drug development that may lead to an HBV cure.
  • Review the planning of combination trials to evaluate for an HBV cure.
  • Identify viral assays used for drug development, including hepatitis B core-related antigen (HBcrAg); HBcAg; quantitative HBV RNA; HBV covalently closed circular DNA (HBV cccDNA; including fine needle aspiration); super sensitive HBsAg assays; quantitative HBeAg; and quantitative HBcAb.